Drugs / AZD4954
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07812077 | Oct → Dec 2026 expected | — | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513571 | Apr → Jul 2026 overdue | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06980428 | May 2025 → Dec 2026 expected | hyperlipidemia | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980428 ↗ |
| Route | Oral | “AZD4954 will be administered orally.” NCT06980428 ↗ |